AstraZeneca

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AstraZeneca and other ETFs, options, and stocks.

About AZN

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology.

CEO

Pascal Soriot

CEOPascal Soriot

Employees

96,100

Employees96,100

Headquarters

Cambridge, Cambridgeshire

HeadquartersCambridge, Cambridgeshire

Founded

1913

Founded1913

Employees

96,100

Employees96,100

AZN Key Statistics

Market cap

286.30B

Market cap286.30B

Price-Earnings ratio

27.14

Price-Earnings ratio27.14

Dividend yield

1.73%

Dividend yield1.73%

Average volume

2.42M

Average volume2.42M

High today

$185.82

High today$185.82

Low today

$182.54

Low today$182.54

Open price

$183.10

Open price$183.10

Volume

1.26M

Volume1.26M

52 Week high

$212.71

52 Week high$212.71

52 Week low

$132.32

52 Week low$132.32

Stock Snapshot

As of today, AstraZeneca(AZN) shares are valued at $184.61. The company's market cap stands at 286.3B, with a P/E ratio of 27.14 and a dividend yield of 1.7%.

On 2026-05-12, AstraZeneca(AZN) stock moved within a range of $182.54 to $185.82. With shares now at $184.61, the stock is trading +1.1% above its intraday low and -0.7% below the session's peak.

Trading activity shows a volume of 1.26M, compared to an average daily volume of 2.42M.

Over the past 52 weeks, AstraZeneca(AZN) stock has traded between a high of $212.71 and a low of $132.32.

AZN News

TipRanks 3h

AstraZeneca Tracks Real-World Sinus Surgery Outcomes in China: What Investors Should Watch

AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter, sharper de...

Benzinga 6h

AstraZeneca's Rare Disease Drug Shows Reduced Dependence On Calcium Supplements

The late-breaking data were presented at the European Congress of Endocrinology in Prague, Czech Republic. Hypoparathyroidism is a rare condition in which the...

TipRanks 7h

AstraZeneca says CALYPSO Phase III trial met composite primary endpoint

AstraZeneca (AZN) said positive results from the CALYPSO Phase III trial showed that eneboparatide, an investigational parathyroid hormone 1 receptor agonist, m...

Analyst ratings

81%

of 31 ratings

Buy

80.6%

Hold

12.9%

Sell

6.5%

More AZN News

TipRanks 1d

AstraZeneca: Buy Rating Reiterated on De-Risked Pipeline, Attractive Valuation and Unchanged £165 Price Target

Sachin Jain, an analyst from Bank of America Securities, maintained the Buy rating on AstraZeneca. The associated price target remains the same with p16,500.00....

TipRanks 7d

AstraZeneca Earnings Call: Oncology Strength, Pipeline Bets

AstraZeneca plc ((GB:AZN)) has held its Q1 earnings call. Read on for the main highlights of the call. Claim 55% Off TipRanks Unlock hedge fund-level data and p...

People also own

Based on the portfolios of people who own AZN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.